EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2

Emerging Company Profile: EvolveImmune Therapeutics
The EVOLVE Platform Is Designed To Address T-Cell Exhaustion • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs